Drug intelligence / Profile preview

gefitinib

Development stage: Approved
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

Gefitinib is a tyrosine kinase inhibitor used primarily for the treatment of non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. It works by inhibiting the EGFR tyrosine kinase, which is often overexpressed in certain carcinomas, leading to uncontrolled cell proliferation. Gefitinib is administered orally once daily.

Brand names: Iressa
Other names: gefitinib (JP18/USAN/INN)GEFITINIB [ORANGE BOOK]Gefitinib, >=98% (HPLC)Gefitinib Tablet

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on gefitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gefitinib.

Explore the full profile